SeqLL is a biotech company that specializes in developing innovative genetic analysis technologies to meet the needs of physicians, patients, and researchers.

History

SeqLL was founded in 2019 by scientists with decades of experience in the field of genetics and biotechnology. Since its inception, the company has achieved tremendous growth and established itself as a leader in gene sequencing and genetic analysis technologies.

Mission

SeqLL’s mission is to develop and commercialize proprietary, cutting-edge genetic diagnostic and research technologies for the benefit of providers, patients, and the research community.

Vision

SeqLL strives to be the global leader in genetic analysis technologies, shaping the future of medical research and improving the lives of patients everywhere.

Key Team

Patrice M. Milos (Independent Director)

David Matthew Pfeffer (Independent Director)

Efrat Shema (Member of Scientific Advisory Board)

Daniel Robert Jones (Co-Founder, President, CEO & Chairman)

L. Frank Kolakowski (Member of Scientific Advisory Board)

Recognition and Awards

SeqLL has been awarded the 2019 Startup of the Year Award byBio-Business Magazine, as well as several other awards from industry organizations.

References

https://in.investing.com/equities/seqll

https://www.crunchbase.com/organization/seqll

seqll.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Douglas Patrick Miscoll (Independent Director)

Timothy McCaffrey (Member of Scientific Advisory Board)

Claes Wahlestedt (Chairman of Scientific Advisory Board)

Products/ Services

Biotechnology, Health Care, Therapeutics

Number of Employees

0 - 50

Headquarters

Woburn, Massachusetts, United States

Established

2013

Company Registration

SEC CIK number: 0001605888

Traded as

NASDAQ:SQL

Social Media

URL

seqll.com

Last updated: Tue Feb 25 2025

We value your privacy

SeqLL

Table of content

Summary